<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Merging data from existing electronic patient records, and electronic hospital discharge and cause of <z:hpo ids='HP_0011420'>death</z:hpo> registers, is a fast and relatively inexpensive method for comparing different treatments with regard to clinical outcome </plain></SENT>
<SENT sid="1" pm="."><plain>This study compared the effects of <z:chebi fb="0" ids="35674">antihypertensive</z:chebi> treatment with <z:chebi fb="0" ids="3347">candesartan</z:chebi> or <z:chebi fb="0" ids="6541">losartan</z:chebi> on <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e>) using Swedish registers </plain></SENT>
<SENT sid="2" pm="."><plain>Patients without previous <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> who were prescribed <z:chebi fb="0" ids="3347">candesartan</z:chebi> (n=7329) or <z:chebi fb="0" ids="6541">losartan</z:chebi> (n=6771) for <z:hpo ids='HP_0000822'>hypertension</z:hpo> during 1999-2007 at 72 Swedish primary care centers were followed for up to 9 years </plain></SENT>
<SENT sid="3" pm="."><plain>Both medications were given according to current recommendations, and there was no difference observed in achieved blood pressures </plain></SENT>
<SENT sid="4" pm="."><plain>The authors have previously shown that <z:chebi fb="0" ids="3347">candesartan</z:chebi> lowered the risk of <z:hpo ids='HP_0000001'>all</z:hpo> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> (primary composite end point) more so than <z:chebi fb="0" ids="6541">losartan</z:chebi> (adjusted hazard ratio, 0.86; 95% confidence interval, 0.77-0.96) </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="0" ids="3347">Candesartan</z:chebi> also had a significantly better effect with regards to reducing the development of <z:hpo ids='HP_0001635'>heart failure</z:hpo>, <z:hpo ids='HP_0011675'>cardiac arrhythmias</z:hpo>, and <z:hpo ids='HP_0004950'>peripheral arterial disease</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>In the present analysis, the authors found that <z:chebi fb="0" ids="3347">candesartan</z:chebi>, compared with <z:chebi fb="0" ids="6541">losartan</z:chebi>, reduced the risk of <z:hpo ids='HP_0000001'>all</z:hpo> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e>, irrespective of sex, age, previous <z:chebi fb="0" ids="35674">antihypertensive</z:chebi> treatment, baseline blood pressure, and presence of <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="7" pm="."><plain>These clinical findings may reflect differences between <z:chebi fb="0" ids="3347">candesartan</z:chebi> and <z:chebi fb="0" ids="6541">losartan</z:chebi> in their binding characteristics to the angiotensin type 1 receptor </plain></SENT>
</text></document>